FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

NCT06801665 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Hua Jiang